Anti cd27 buv395

Manufactured by BD

Anti-CD27-BUV395 is a fluorochrome-conjugated monoclonal antibody that recognizes the CD27 antigen. CD27 is a member of the tumor necrosis factor receptor superfamily and is expressed on various immune cell types. This antibody can be used for the identification and analysis of CD27-positive cells by flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Anti-CD27 (32 citations)

2 protocols using anti cd27 buv395

Quantification of Antigen-Specific CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Co-cultures containing peptide-pulsed DCs and PBMCs at a ratio of 1:10 (final concentrations 2 × 10⁵ DCs/ml and 2 × 10⁶ PBMCs/ml) were harvested after 1 week. Cultures with DCs that had not been peptide-pulsed served as controls. T cells specific for the MelanA peptide were detected with HLA-A0201-PE ELAGIGILTV tetramer (produced in house according to Rodenko et al.^{34 (link)}). Harvested cells were stained with the tetramer for 15 min, then anti-CD3-APC-H7, anti-CD4-AlexaFluor700, anti-CD8-PE-Cy7, anti-CD56-BV421, anti-CD16-FITC, anti-CD69-APC, and anti-CD27-BUV395 (all from BD Bioscience) were added and incubated for another 20 min. After washing twice with phosphate buffered saline, cells were acquired on a FACS Fortessa (BD Bioscience). CD8⁺ T cells and NK cells were distinguished and characterized via expression of CD3, CD56, CD8, and CD69. The gating strategy is depicted in Supplemental Figure S8.

Bosch N.C., Voll R.E., Voskens C.J., Gross S., Seliger B., Schuler G., Schaft N, & Dörrie J. (2019). NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells. Therapeutic Advances in Medical Oncology, 11, 1758835919891622.

+ Open protocol

+ Expand

Comprehensive Immunophenotyping of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-CD19 APC-Cy7, anti-CD38 PerCp-Cy5.5, anti-CD4 PE-Cy7, anti-CD25 PerCP-Cy5.5, anti-CD86 APC, anti-CD80 BV421, anti-CD45RA BV605, anti-ICOS PE, anti-CD21 PE-Cy7, anti-CD80 BV421, anti-CD27 PerCp-Cy5.5, anti-PD-1 APC, anti-CD45RA APC-Cy7, anti-HLA-DR BV605, anti-CD11c AF700, anti-CD86 BV711, anti-CD95 BV650, anti-IgD BV786, anti-FCRL5 APC, anti-CXCR3 BV421, anti-CCR6 BV605, anti-CD19 BV650, anti-CD19 BV605, anti-PD-L1 BV421, anti-PD-L2 PE, anti-ICOS-L PE, anti-OX40L PE, anti-IL-10 PE, anti-IL-10 APC, anti-TNF-α APC-Cy7 (all obtained from BioLegend); anti-IgD FITC and anti-IgD PE (both from Southern Biotech); anti-CD27 PE (Dako); and anti-CD21 PE-Cy7, anti-CD69 FITC, anti-HLA-DR FITC, anti-CD27 BV605, anti-CD40 FITC, anti-CD40L PE, anti-ICAM-1 PE, anti-CXCR5 BUV395 and anti-CD27 BUV395 (all from BD Biosciences).

Reincke M.E., Payne K.J., Harder I., Strohmeier V., Voll R.E., Warnatz K, & Keller B. (2020). The Antigen Presenting Potential of CD21low B Cells. Frontiers in Immunology, 11, 535784.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!